Atypical Recurrence of Parathyroid Carcinoma Following Infliximab Therapy in a Patient with Ulcerative Colitis
Aace Clinical Case ReportsPeer ReviewedFelona Gunawan +12020Journals
Parathyroid carcinoma (PTC) has a high rate of recurrence, which typically occurs within 5 years of diagnosis involving locoregional sites. Immunosuppressive therapies pose a theoretical increased risk of malignancy. We report an atypical case of PTC recurrence in a patient receiving infliximab therapy for ulcerative colitis (UC).
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support